TEVA vs. TAK, ARGX, BNTX, ONC, INSM, SMMT, ITCI, GMAB, RDY, and MRNA
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries vs. Its Competitors
Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
Teva Pharmaceutical Industries has a consensus price target of $24.71, suggesting a potential upside of 54.32%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 3 mentions for Teva Pharmaceutical Industries. Takeda Pharmaceutical's average media sentiment score of 1.07 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.
Takeda Pharmaceutical has a net margin of 2.36% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Takeda Pharmaceutical's return on equity.
9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
This page (NYSE:TEVA) was last updated on 7/17/2025 by MarketBeat.com Staff
Free TEVA Stock Alerts